Bristol-Myers Squibb (NYSE:BMY) Shares Sold by KLCM Advisors Inc.

KLCM Advisors Inc. lessened its holdings in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 4.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 532,539 shares of the biopharmaceutical company's stock after selling 23,043 shares during the period. Bristol-Myers Squibb makes up approximately 3.5% of KLCM Advisors Inc.'s portfolio, making the stock its 4th biggest holding. KLCM Advisors Inc.'s holdings in Bristol-Myers Squibb were worth $30,120,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. AlphaCentric Advisors LLC purchased a new position in Bristol-Myers Squibb in the fourth quarter valued at about $1,111,000. Nicholas Hoffman & Company LLC. increased its stake in Bristol-Myers Squibb by 1.5% in the 4th quarter. Nicholas Hoffman & Company LLC. now owns 31,142 shares of the biopharmaceutical company's stock valued at $1,761,000 after purchasing an additional 451 shares in the last quarter. New Jersey Better Educational Savings Trust acquired a new position in Bristol-Myers Squibb during the fourth quarter worth $218,000. Americana Partners LLC purchased a new stake in Bristol-Myers Squibb during the fourth quarter worth $12,083,000. Finally, Capital Performance Advisors LLP grew its holdings in Bristol-Myers Squibb by 24.7% in the fourth quarter. Capital Performance Advisors LLP now owns 6,186 shares of the biopharmaceutical company's stock valued at $350,000 after purchasing an additional 1,225 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. BMO Capital Markets lifted their price target on Bristol-Myers Squibb from $57.00 to $61.00 and gave the stock a "market perform" rating in a research note on Tuesday, November 12th. Cantor Fitzgerald lifted their target price on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 4th. Leerink Partnrs raised shares of Bristol-Myers Squibb from a "hold" rating to a "strong-buy" rating in a report on Tuesday, November 12th. Daiwa America raised shares of Bristol-Myers Squibb from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, November 13th. Finally, Daiwa Capital Markets raised Bristol-Myers Squibb from a "neutral" rating to an "outperform" rating in a research note on Wednesday, November 13th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, Bristol-Myers Squibb currently has a consensus rating of "Hold" and a consensus target price of $57.86.

Insider Transactions at Bristol-Myers Squibb

In other news, EVP Samit Hirawat purchased 1,823 shares of the stock in a transaction on Friday, February 14th. The stock was purchased at an average price of $54.84 per share, with a total value of $99,973.32. Following the completion of the transaction, the executive vice president now owns 63,932 shares in the company, valued at approximately $3,506,030.88. The trade was a 2.94 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Trading Up 1.5 %

NYSE BMY traded up $0.82 during trading hours on Thursday, hitting $55.80. 8,949,679 shares of the company's stock were exchanged, compared to its average volume of 10,879,409. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The firm has a market capitalization of $113.23 billion, a P/E ratio of -12.62, a price-to-earnings-growth ratio of 2.02 and a beta of 0.45. The business's 50 day moving average is $57.00 and its 200-day moving average is $54.23. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $61.10.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. As a group, analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd were paid a dividend of $0.62 per share. The ex-dividend date was Friday, January 3rd. This is a boost from Bristol-Myers Squibb's previous quarterly dividend of $0.60. This represents a $2.48 annualized dividend and a dividend yield of 4.44%. Bristol-Myers Squibb's payout ratio is currently -56.11%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.